Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. develops RNA-targeted medicines and reports news around marketed medicines and a pipeline in neurology, cardiometabolic disease and other high-need areas. Company updates commonly address commercial performance for TRYNGOLZA, financial results, R&D revenue from partnerships, and progress across antisense oligonucleotide programs.
Clinical and regulatory news also covers programs such as olezarsen for severe hypertriglyceridemia, zilganersen for Alexander disease, and partner-developed bepirovirsen for chronic hepatitis B. Governance and investor-relations releases include annual meeting materials, board composition changes, and healthcare conference presentations.
Ionis (Nasdaq: IONS) appointed Ludwig Hantson, Ph.D., a veteran biopharmaceutical executive, to its Board of Directors, effective immediately. He previously served as CEO of Alexion and Baxalta and held senior roles at Baxter Bioscience, Novartis and Johnson & Johnson.
Ionis highlights his experience leading complex global organizations in rare and specialty diseases as it prepares for multiple new commercial launches and continued scaling as a fully integrated biotechnology company. Ionis also recently added Peter Reikes to the board and announced the retirement of directors Joseph Wender and Lynne Parshall.
Ionis (Nasdaq: IONS) will present new analyses from the Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG) at the 2026 ADA, NLA and ENDO congresses.
According to Ionis, prior CORE/CORE2 results showed highly statistically significant reductions in fasting triglycerides and acute pancreatitis events, with favorable safety and tolerability. Olezarsen’s U.S. FDA Priority Review has a target action date of June 30, 2026.
Ionis (Nasdaq: IONS) reported that partner GSK announced positive pivotal Phase 3 data for bepirovirsen in chronic hepatitis B. Six-month treatment achieved a 19% functional cure rate overall and 26% in patients with lower baseline HBsAg (≤1000 IU/mL), versus 0% with standard of care.
Bepirovirsen is under FDA priority review with Breakthrough and Fast Track status, and is also under review in Europe, Japan and China. Ionis is eligible for additional regulatory and sales milestones plus 10–12% tiered royalties on net sales.
Ionis (Nasdaq: IONS) announced that partner Biogen reported topline Phase 2 CELIA results for diranersen (BIIB080) in early Alzheimer’s disease. CELIA did not meet its primary dose-response endpoint on CDR-SB at Week 76, but showed tau biomarker reductions and cognitive effects across all studied doses.
Prespecified analyses indicated slowed clinical decline, especially at 60 mg every 24 weeks. Tau reductions in CSF and PET were maintained over the dosing period. Safety and tolerability were generally in line with the Phase 1b study, though serious adverse events were more frequent at the highest dose. Biogen plans to advance diranersen to registrational development.
Ionis (Nasdaq: IONS) will hold a virtual Annual Meeting of Stockholders and a corporate update on Thursday, June 4, 2026. The Annual Meeting is 5:00–5:15 p.m. ET and the corporate update at 5:30 p.m. ET, presented by CEO Brett P. Monia, Ph.D.
Stockholders of record at close of business on April 7, 2026 may join the Annual Meeting webcast at www.virtualshareholdermeeting.com/IONS2026. The corporate update webcast is available live and will have a limited-time archived replay at the event webcasts URL.
Ionis (Nasdaq: IONS) announced management will present fireside chats at three investor conferences in May–June 2026: Bank of America Health Care (May 12), RBC Capital Markets Global Healthcare (May 19), and Goldman Sachs Global Healthcare (June 10).
Live webcasts and replays will be available on the Investors & Media section of the Ionis website; replays posted within 48 hours and archived for a limited time.
Ionis (Nasdaq: IONS) reported Q1 2026 revenue of $246M versus $132M a year earlier (an 87% increase). Q1 product sales: TRYNGOLZA $27M, DAWNZERA $16M; R&D revenue $138M including approximately $95M in milestone payments. Operating expenses were $364M and loss from operations was $(118)M. Cash and short-term investments were $1.9B after using a $633M escrow for convertible-note maturity. Company raised 2026 revenue guidance to $875–900M and set TRYNGOLZA/DAWNZERA sales targets of $100–110M and $110–120M, respectively.
Ionis (Nasdaq: IONS) partner GSK announced the FDA accepted the NDA for bepirovirsen for Priority Review, granted Breakthrough Therapy designation, and set a PDUFA date of October 26, 2026.
Regulatory action follows Phase 3 B-Well 1 and 2 trials reporting statistically significant, clinically meaningful functional cure rates versus standard of care; data to be presented at EASL 2026. Bepirovirsen is also under review with EMA, NMPA, and MHLW, and carries tiered royalties of 10–12% to Ionis under the GSK license.
Ionis (Nasdaq: IONS) reported positive pivotal study results for zilganersen in Alexander disease, with the trial meeting its primary endpoint and a PDUFA date set for September 22, 2026.
Key findings: 10MWT gait stabilization +33.3% versus control (p=0.041), GMFM-88 +22.9 points in ages 2–4 (nominal p=0.034), plasma GFAP −33.6% (nominal p=0.003). Safety was described as favorable with fewer serious TEAEs versus control.
Ionis (Nasdaq: IONS) will host a live webcast to discuss its first quarter 2026 financial results on Wednesday, April 29 at 8:30 a.m. ET.
According to Ionis, the webcast will highlight progress on key programs and will be available live and as a limited-time replay at the company investor events page.